XTLB 6-K: Doron Turjeman exits; CEO Noam Band added to board

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. announced a board change. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors due to personal reasons. The company stated his resignation was not the result of any disagreement with the company or its management. Noam Band, the Company’s Chief Executive Officer, was appointed to the Board of Directors in his place, effective immediately.

XTL is an IP portfolio company that owns 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio around hCDR1 for treating lupus (SLE). The company trades on Nasdaq (XTLB) and the TASE (XTLB.TA).

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October, 2025

Commission File Number: 001-36000 

XTL Biopharmaceuticals Ltd.

(Translation of registrant’s name into English)

26 Ben-Gurion St.

Ramat Gan

5112001 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. (the “Company”) due to personal reasons. Mr. Turjeman’s resignation was not the result of any disagreement with the Company or its management. Noam Band, the Company Chief Executive Officer, was appointed to serve as a member of the Board of Directors in his place, effective immediately.

About XTL Biopharmaceuticals Ltd. (XTL)

XTL is an IP portfolio company. The Company holds 100% of the share capital of The Social Proxy Ltd., a web data company and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE).

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 3 611 6666

Email: ir@xtlbio.com

www.xtlbio.com

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL BIOPHARMACEUTICALS LTD.
Date: October 22, 2025	By:	/s/ Shlomo Shalev
		Chairman of the Board of Directors

2

FAQ

What did XTLB disclose in its Form 6-K?

XTL Biopharmaceuticals reported a board change: Doron Turjeman resigned and CEO Noam Band was appointed to the Board of Directors.

Why did Doron Turjeman resign from XTLB’s board?

He resigned due to personal reasons, and the company stated there was no disagreement with the company or management.

Who joined XTLB’s board and when?

Noam Band, the Chief Executive Officer, joined the Board of Directors effective immediately following the resignation.

Was there any disagreement leading to the resignation at XTLB?

The company stated the resignation was not the result of any disagreement with the company or its management.

On which exchanges does XTLB trade?

XTL trades on the Nasdaq Capital Market under XTLB and on the Tel Aviv Stock Exchange as XTLB.TA.

What does XTL Biopharmaceuticals do?

XTL is an IP portfolio company; it owns 100% of The Social Proxy Ltd. and has sublicensed an IP portfolio surrounding hCDR1 for lupus (SLE).

How can investors contact XTLB Investor Relations?

By phone at +972 3 611 6666 or email at ir@xtlbio.com.